A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  International Immunopharmacology

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.INTIMP.2004.11.010PMID 15683857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.

  2003cited by this paper
• Intravenous immunoglobulin in clinical practice

  2003cited by this paper
• Antibody-directed therapy: past, present, and future.

  2001cited by this paper
• Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents

  1999cited by this paper
• Adverse Effects of Intravenous Immunoglobulin Therapy

  1999cited by this paper
• Human intravenous immunoglobulin in primary and secondary antibody deficiencies.

  1997cited by this paper
• Appropriate therapeutic use of immunoglobulin.

  1996cited by this paper
• Tolerability and Kinetics of a Solvent‐Detergent‐Treated Intravenous Immunoglobulin Preparation in Hypogammaglobulinaemia Patients

  1995cited by this paper
• Human spongiform encephalopathy: The national institutes of health series of 300 cases of experimentally transmitted disease

  1994cited by this paper
• Toxicity of rapidly infused concentrated intravenous immune globulin.

  1992cited by this paper
• Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.

  1991cited by this paper
• Immunoglobulin replacement therapy by self-infusion at home.

  1988cited by this paper
• Intravenous immunoglobulin home treatment for patients with primary immunodeficiency diseases.

  1986cited by this paper
• Elimination of infectious retroviruses during preparation of immunoglobulins

  1986cited by this paper

• Is there evidence for recommending specific intravenous immunoglobulin formulations? A systematic review of head-to-head randomized controlled trials.

  2015cites this paper
• Post‐marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections

  2013influential citation
• Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies

  2012cites this paper
• Activación y función cooperadora del linfocito T en la inmunodeficiencia variable común

  2011cites this paper
• Activación y función cooperadora del linfocito T en la inmunodeficiencia variable común

  2011cites this paper
• The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline.

  2010cites this paper
• Stability of equine IgG antivenoms obtained by caprylic acid precipitation: towards a liquid formulation stable at tropical room temperature.

  2009cites this paper
• Safety of Intravenous Immunoglobulin in the Treatment of Juvenile Dermatomyositis: Adverse Reactions Are Associated With Immunoglobulin A Content

  2008cites this paper
• VIII Reunión del Grupo Español de Inmunodeficiencias Primarias (II)

  2008cites this paper
• Adverse reactions and pathogen safety of intravenous immunoglobulin.

  2007cites this paper